NR-55342来自SARS相关冠状病毒2的刺突糖蛋白受体结合域(RBD),具有C端Avi和组氨酸标签的V367F变体,来自HEK293细胞(蛋白质）的重组
产品图片
货号/SKU
NR-55342
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、1
产品描述信息
NR-55342?? Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related Coronavirus 2, V367F Variant with C-Terminal Avi and Histidine Tags, Recombinant from HEK293 Cells(Proteins)|SARS-Related Coronavirus 2|Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related Coronavirus 2, V367F Variant with C-Terminal Avi and Histidine Tags, Recombinant from HEK293 Cells|-80°C (Note: Storage at warmer temperatures is not recommended due to a low bioburden.)|BPS BioscienceAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related Coronavirus 2, V367F Variant with C-Terminal Avi and Histidine Tags, Recombinant from HEK293 Cells, NR-55342.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
A recombinant form of the spike glycoprotein receptor binding domain (RBD) from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), V367F variant was produced by transient transfection in human embryonic kidney HEK293 cells, purified by affinity chromatography and biotinylated. NR-55342 lacks the signal sequence, contains 223 residues of the SARS-CoV-2 spike glycoprotein RBD (amino acid residues R319 to F541) and features a C-terminal AviTag? BirA biotinylation acceptor sequence fused to a hexa-histidine tag. NR-55342 is a variant of SARS-CoV-2 which contains the V367F mutation in the S glycoprotein RBD as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55342 has a theoretical molecular weight of 28,000 daltons. The crystal structure for the wild-type S glycoprotein from SARS-CoV-2 has been solved at 2.8 ? resolution (PDB: 6VXX).
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. SARS-CoV-2 variants with the S glycoprotein V367F mutation were found frequently during the early transmission phase and show increased binding affinity to ACE2 compared to wild-type.
Each vial contains approximately 50 ?g of purified recombinant protein in 8 mM phosphate pH 7.4, 110 mM NaCl, 2.2 mM KCl and 20% glycerol.
Additional information and tools are available at ViPR (Virus Pathogen Resource).
A recombinant form of the spike glycoprotein receptor binding domain (RBD) from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), V367F variant was produced by transient transfection in human embryonic kidney HEK293 cells, purified by affinity chromatography and biotinylated. NR-55342 lacks the signal sequence, contains 223 residues of the SARS-CoV-2 spike glycoprotein RBD (amino acid residues R319 to F541) and features a C-terminal AviTag? BirA biotinylation acceptor sequence fused to a hexa-histidine tag. NR-55342 is a variant of SARS-CoV-2 which contains the V367F mutation in the S glycoprotein RBD as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55342 has a theoretical molecular weight of 28,000 daltons. The crystal structure for the wild-type S glycoprotein from SARS-CoV-2 has been solved at 2.8 ? resolution (PDB: 6VXX).
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. SARS-CoV-2 variants with the S glycoprotein V367F mutation were found frequently during the early transmission phase and show increased binding affinity to ACE2 compared to wild-type.
Each vial contains approximately 50 ?g of purified recombinant protein in 8 mM phosphate pH 7.4, 110 mM NaCl, 2.2 mM KCl and 20% glycerol.
Additional information and tools are available at ViPR (Virus Pathogen Resource).
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.此限制的订单将在发货前发送到NIAID批准.
来自严重急性呼吸综合征相关冠状病毒2（SARS-COV-2）的穗糖蛋白受体结合结构域（RBD）的重组形式，通过瞬态转染在人胚胎肾HEK293细胞中产生V367F变体，通过亲和色谱法纯化和生物素化. NR-55342缺乏信号序列，含有223个残基SARS-COV-2穗糖蛋白RBD（氨基酸残基R319至F541），并具有融合的C-末端Avitag TM Bira Biotinylation受体序列
Hexa-hastiatine标签. NR-55342是SARS-COV-2的变体，其含有与SARS-COV-2参考序列（Genpept： QHD43416 ）. nr-55342有一个
理论分子量为28,000道尔顿.来自SARS-COV-2的野生型糖蛋白的晶体结构已经解决了2.8埃分辨率（PDB： 6VXX ）.
S糖蛋白介导与宿主血管紧张素转化酶2（ACE2）的病毒结合.该蛋白质形成三聚体，并且当与宿主受体结合时，允许融合病毒和细胞膜.在早期传输阶段常见地发现SARS-COV-2具有S糖蛋白V367F突变的变体，与野生型相比，对ACE2的结合与ACE2的结合亲和力增加.
每个小瓶在8mM磷酸pH 7.4,110mM NaCl，2.2mM KCl和20％甘油中含有大约50μg的纯化重组蛋白.
vipr （病毒病原体资源）提供了附加信息和工具.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2022-04-01
2022-04-01
2021-12-21
2024-09-22
2022-04-01
2024-10-20
2021-12-21
2022-03-31
2024-05-19
2022-04-01
2021-12-13
2024-06-25
2022-04-01